Safety Data for 32 patients in trial
As of the data cutoff date of September 25, 2023, bezuclastinib continues to demonstrate a differentiated safety and tolerability profile across doses. The majority of adverse events were low grade and reversible and there were no related cognitive impairment or bleeding events reported. Related serious adverse events were reported in four patients including Grade 4 thrombocytopenia, Grade 3 hypersensitivity (mediator flare), Grade 3 leishmaniasis, and Grade 3 drug induced liver injury in a patient who was subsequently found to have biliary tract outflow obstruction. Nine patients required dose reduction due to adverse events, six of whom were at the 400mg dose, and three patients discontinued due to adverse events.Monday, December 11, 2023
Marker: Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and remains in complete response six months after MT-601 treatment
Regeneron Data on Follicular Lymphoma Showed Compelling Responses
Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR
Oral presentation showcased overall maintenance of patient-reported outcomes from baseline to 50 weeks during investigational odronextamab treatment, complementing the overall efficacy and safety profile in this heavily pretreated and highly refractory patient population
AbbVie, Genmab present new data for bispecific antibody epcoritamab
AbbVie (ABBV) and Genmab (GMAB) announced that adult patients with relapsed/refractory follicular lymphoma previously treated with two or more prior therapies experienced strong and durable responses with high overall response and complete response rates when treated with epcoritamab, an investigational, subcutaneously administered T-cell engaging bispecific antibody. More than half of patients who responded to treatment in the study remained responsive to treatment at the time of data analysis. Updated data from this study include an optimized, step-up dosing schedule showing reduced incidence and severity of cytokine release syndrome, a notable side effect from immune-engaging cancer treatments. No new safety signals were detected. TEAEs leading to treatment discontinuation occurred in 19% of patients, and death related to TEAEs occurred in 13 patients.
Moderna, Merck begin late-stage study for mRNA cancer therapy
Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.
The therapy, V940, belongs to a class of treatments called m-RNA-based individualized neoantigen therapy (INT) and is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumor.
Recruitment for the study has begun globally with the first patients enrolled in Australia, the companies said.
Moderna and Merck started a late-stage study in July testing the combination therapy in patients with melanoma, the most deadly form of skin cancer.
https://finance.yahoo.com/news/1-moderna-merck-begin-stage-122013822.html
Altamira partial spin-off of Bentrio 1st step in transition to become ‘pure play’ RNA delivery
- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ET
- Partial spin-off of Bentrio® business first step in transition to become ‘pure play’ RNA delivery company
- Transition expected to complete in 2024 through partnering of further legacy assets
- Spending levels and cash burn aligned with strategic repositioning and to decrease significantly in 2024
- Free of financial debt following early repayment of convertible loan
- Expects to regain full compliance with Nasdaq continued listing rules through reverse split
Altamira management will hold an investor teleconference on Monday, December 11, 2023, at 8:30 a.m. ET to discuss its investor and business update. Founder, Chairman, and CEO Thomas Meyer will deliver prepared remarks that will be available via teleconference or webcast with audio and presenter-controlled slides.
Event: Altamira Therapeutics Business Update Call
Date: Monday, December 11, 2023
Time: 8:30 a.m. ET (5:30 a.m. PT)
Webcast URL: https://edge.media-server.com/mmc/p/k7s8zdkg
Register for Teleconference:
- Online: https://register.vevent.com/register/BIc43c7804270544c6bac8d34949816636
- Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
- Select a method for joining the call.
- A dial-in number and unique PIN are displayed to connect directly from your phone.
- Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a US number.
A replay of the call will be available after the live event and accessible through the webcast link: https://edge.media-server.com/mmc/p/k7s8zdkg
Subscribe to:
Posts (Atom)